Kornimate/medical-research-clean huggingface dataset:
pet/mr in locally advanced nasopharyngeal carcinoma

Conditions: Nasopharyngeal Carcinoma; PET/MR

Summary: pet/mr in locally advanced nasopharyngeal carcinoma


Eligibility criteria:
inclusion criteria: * patients with newly histologically confirmed non-keratinizing carcinoma. * tumor staged t1-4n0-3m0 （according to the 8th ajcc staging system） * performance status: kps\>70 * with normal liver function test (alt, ast \<1.5uln) * renal: creatinine clearance \>60ml/min * without hematopathy,marrow: wbc \>4\*109/l, hgb\>80g/l, and plt\>100\*109/l. * written informed consent exclusion criteria: * adenocarcinoma * age \>70 * prior malignancy (except adequately treated carcinoma in-situ of the cervix or · basal/squamous cell carcinoma of the skin) * previous chemotherapy or radiotherapy (except non-melanomatous skin cancers outside the intended rt treatment volume) * patient is pregnant or lactating * any severe intercurrent disease, which may bring unacceptable risk or affect the compliance of the trial, for example, unstable cardiac disease requiring treatment, renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose \>1.5×uln), or emotional disturbance.
a study of transcatheter aortic valve replacement case selection and valve sizing using the abc bicuspid sizing algorithm

Conditions: Aortic Stenosis

Summary: the goal of this study is to learn what effects the abc bicuspid sizing algorithm has on the clinical outcomes of patients with bicuspid aortic stenosis after having a transcatheter aortic valve replacement (tavr) using the sapien 3 valve. the main questions the study aims to answer are: 1. does the abc bicuspid sizing algorithm increase the technical success at exit from the procedure room? 2. does the abc bicuspid sizing algorithm increase the device success at 30 days after the procedure? participants already being evaluated for a tavr as part of their regular medical care for bicuspid aortic stenosis will have their diagnostic images assessed using the abc bicuspid sizing algorithm to help determine their procedure type and valve size. they will have visits 30 days and one year after their procedure.

this is a multi-centre, international, prospective cohort study. approximately 290 patients who are clinically eligible for transcatheter aortic valve replacement (tavr) will be enrolled. using information collected with the abc bicuspid sizing algorithm, physicians will make a treatment allocation between tavr and surgical aortic valve replacement (savr), and determine valve sizing and deployment for tavr-treated patients. included in the algorithm use is the utilization of gated computed tomography evaluation or artificial intelligence-based simulation models in select cases with borderline feasibility. the findings of these additional assessments will be shared with the treating physicians for consideration in the final treatment decision. of the 290 patients, an estimated 230 will be recommended to have tavr. data will be collected from tavr-treated patients at baseline, procedure, hospital discharge, and 30 days and one year after the procedure. data will only be collected from savr-treated patients at baseline and procedure. sites in canada, latin america, the middle east, and asia pacific will participate.

Eligibility criteria:
inclusion criteria: * have bicuspid aortic valve disease * have severe aortic stenosis or mixed aortic stenosis and regurgitation requiring treatment * have no other condition requiring surgical intervention * have had a tavr ct scan (retrospectively gated contrast enhanced acquisition) that is of diagnostic quality and includes multiphase reconstructions of the aortic root at the minimum available slice thickness (with at least three systolic and one diastolic phases) * would be treated with a sapien 3 valve if found to be anatomically suitable for tavr * have a suitable access route for tavr with a sapien 3 valve exclusion criteria: * are treated with tavr using a device other than a sapien 3 valve * are unable to be treated with tavr due to intercurrent illness, clinical instability, or death on waitlist after being accepted for tavr

Keywords: bicuspid aortic stenosis transcatheter aortic valve replacement
a phase 1 study to explore the cardiac pharmacodynamics of mt-1303

Conditions: Relapsing-remitting Multiple Sclerosis

Summary: the purpose of this study is to explore the cardiac pharmacodynamics, safety and tolerability of mt-1303 in healthy subjects.


Eligibility criteria:
inclusion criteria: * healthy and free from clinically significant illness or disease. * male and female subjects of non-childbearing potential aged 18 to 55 years. * normal or non-clinically significant 12-lead ecg. * holter recording with no clinically significant abnormalities. * systolic blood pressure: 90 to 140 mmhg, diastolic blood pressure: 50 to 90 mmhg exclusion criteria: * a history of severe adverse reaction or allergy to any medical product. * clinically significant endocrine, thyroid, hepatic, respiratory, gastrointestinal, renal, cardiovascular disease, eye disorder or history of psychiatric/psychotic disorder. * a history of tuberculosis. * have a positive hbsag, hbcab, hcvab or hiv-1 and hiv-2 test. * previously having received mt-1303, fingolimod, or any other sphingosine-1-phosphate receptor modulators. * clinical relevant abnormal medical history, or physical findings or laboratory values. * clinically significant 12-lead ecg abnormalities. * clinical relevant abnormal findings in echocardiograph.
requests for euthanasia and assisted suicide

Conditions: Palliative Care; End of Life; Euthanasia; Assisted Suicide; Qualitative Research

Summary: this study take place in the palliative care units of burgundy-franche-comté regions and at the maison médicale jeanne garnier. the main aim of this project is to analyze and understand the meaning of explicit requests to hasten death (euthanasia and assisted suicide). this involves conducting interviews with patients, carers to whom the request has been expressed and a relative chosen by the patient. this study aims to describe the request over time. this will be done through two series of interviews, one as soon as it is first expressed, then one week later.


Eligibility criteria:
inclusion criteria: * adult not under guardianship or curatorship, * hospitalized in palliative care units of bourgogne-franche-comté region and in the maison médicale jeanne garnier in paris, * at the end of life due to advanced stage disease or a major change in the state of health of an elderly person, * they have made an explicit request for euthanasia or assisted suicide, * they are in capacity to meet researchers for interview, * having consented to interviews, * they are covered by the french social security system. exclusion criteria: * adult under guardianship or curatorship, * they are underage, * they are not hospitalized in palliative care unit of bourgogne-franche-comté region and in the maison médicale jeanne garnier, * the request was expressed by another person or not explicit, * they didn't consent to interviews, * the request appears in the context of a situation other than illness or a general change in state of health * they are not in capacity to meet researchers for interviews.
metabolic changes in blood samples from patients with acute myeloid leukemia

Conditions: Recurrent Adult Acute Myeloid Leukemia; Untreated Adult Acute Myeloid Leukemia

Summary: this research trial studies metabolic changes in blood samples from patients with acute myeloid leukemia. studying samples of blood from patients with acute myeloid leukemia in the laboratory may help doctors learn more about cancer and the development of drug resistance.

primary objectives: i. to determine the metabolic adaptations that occur following exposure to standard chemotherapeutic agents using peripheral blood mononuclear cells from acute myeloid leukemia (aml) patients. outline: patients undergo collection of peripheral blood mononuclear cell (pbmc) samples for analysis via cell isolation, glycolytic flux and oxygen consumption assays, viability assays, and western blot at baseline, 24, 48, and 72 hours after starting chemotherapy.

Eligibility criteria:
inclusion criteria: * patients scheduled to initiate chemotherapy for either an initial diagnosis of aml or relapsed aml * starting the initial induction phase of therapy * exposure to hydroxyurea is acceptable but must be noted at the time of sample collection * ability to understand and the willingness to sign an institutional review board (irb)-approved informed consent exclusion criteria: * received at least one dose of chemotherapy during the current cycle (excluding hydroxyurea).
pain, range of motion, edema, sensibility, strength (press) & self-reported function create a comprehensive score

Conditions: Hand Injuries and Disorders; Upper Extremity Problem

Summary: the aim of this study is to examine the development of a conceptual framework and provide evidence for reliability of a comprehensive hand therapy evaluation score. this approach provides a new standardized tool for upper extremity (ue) evaluation. components of pain, range of motion (rom), edema, sensibility, strength (press), and self-reported function were combined to create a baseline. each assessment tool used for the press to function approach assists in determining appropriate interventions.

in this study, investigators used the innovative press to function approach and composite score to describe the development and piloting of a systematic standard for upper extremity evaluation. using existing instruments with substantial evidence of validity and reliability is more cost-effective than starting from scratch to develop and validate an instrument. this approach and score will provide occupational therapists an accurate measure to track the progression of a patient. the hypothesis for this study is press to function components will demonstrate utility for measuring clinical and patient-reported function when used as a comprehensive assessment tool.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of upper extremity disorder as the primary diagnosis * surgical and nonsurgical diagnoses * age 21 years or older exclusion criteria: * concomitant diseases (i.e cerebralvascular accident, cerebral palsy, spinal cord injury) * full body lymphedema * individuals who did not complete at least one reassessment

Keywords: press to function pain range of motion edema sensation strength quick dash upper extremity hand
influence of vitamin d on vascular function in adolescents and young adults with type 1 diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: the purpose of this study is to study the role of low vitamin d levels on the health of blood vessels or vascular function in adolescents and young adults with type 1 diabetes.

vitamin d deficiency is known to be common in patients with type 1 diabetes. studies in adults have shown that vitamin d deficiency is associated with cardiovascular events such as stroke, myocardial infarction and peripheral arterial disease. however, the impact of this deficiency on vascular health in adolescents with diabetes has not been examined. furthermore given that endothelial dysfunction is reversible, early detection of this process may have therapeutic and prognostic implications in this population.

Eligibility criteria:
inclusion criteria: 1. diagnosed with type 1 diabetes, according to canadian diabetes association guidelines 2. diagnosed with type 1 diabetes for at least 2 years 3. between the ages of 12 and 18 years exclusion criteria: 1. previous organ transplantation 2. diagnosed with familial hypercholesterolemia 3. active smoker 4. receiving lipid lowering medications 5. receiving anti hypertensive medication 6. significant chronic medical illness, including granulomatous disease 7. history of hypertension 8. bmi \>95%tile 9. known renal failure 10. hba1c greater than 12% on two successive occasions 11. known peripheral vascular disease 12. known hypercalcemia

Keywords: type 1 diabetes adolescents and young adults vitamin d cardiovascular disease
incidence of relapse and post-kala-azar dermal leishmaniasis in south sudan

Conditions: Leishmaniasis; Leishmaniasis, Visceral; Post-kala-azar Dermal Leishmaniasis

Summary: this study aims to describe the burden of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis.

this prospective, observational cohort study aims to describe the burden of post-kala-azar dermal leishmaniasis and visceral leishmaniasis relapse in a cohort of patients discharged after successful treatment of primary visceral leishmaniasis from a hospital in lankien, south sudan.

Eligibility criteria:
inclusion criteria: * primary visceral leishmaniasis patients who had a confirmed (serological and/or parasitological) diagnosis at admission, and who were discharged after successful treatment * availability for follow up visits * provision of informed consent, and in the case of minors 12 to 17 years of age, assent as well exclusion criteria: * unavailability for follow-up visits due to distance, inaccessibility, or refusal to participate * diagnosis of prior primary visceral leishmaniasis done only on clinical basis

Keywords: leishmaniasis leishmaniasis, visceral post-kala-azar dermal leishmaniasis south sudan kala-azar
sexual health of sub-saharan african migrant women recently diagnosed with hiv in île-de-france: missed opportunities for prevention

Conditions: HIV Infections; Sexual Health; Migrants; Women's Health; Health Services Accessibility; Sub-Saharan Africa; Risk-Taking; Vulnerable Populations

Summary: this study looks at the sexual health of women from sub-saharan africa who recently found out they have hiv after arriving in île-de-france. it aims to understand their risk factors and identify missed chances for hiv testing and prevention. the goal is to improve care and support for these women by learning more about their experiences and the challenges they face.


Eligibility criteria:
inclusion criteria: * sub-saharan african migrant women recently diagnosed with hiv (from 2021 onward) * hiv diagnosis made on french territory * aged 18 years or older exclusion criteria: * inability to inform the patient about the study due to a language barrier or other obstacle * hiv diagnosis made before 2021 * hiv diagnosis made in the country of origin * under 18 years of age
study of the location of motor cortical stimulation electrodes in chronic neuropathic refractory patients

Conditions: Neuropathic Pain

Summary: cortical stimulation has been used since 1991 to treat neuropathic pain. however, the underlying mechanisms are still incompletely understood and under-studied. in this protocol, the investigators aim to study the myeloarchitectonic and functional characteristics of areas activated by cortical epidural electrodes and to determine their relation to therapy response in chronic neuropathic refractory pain patients.


Eligibility criteria:
inclusion criteria * adults * patient implanted with a motor cortical stimulation system for chronic neuropathic refractory pain, * patient with available postoperative scanner exclusion criteria: none
performance of long-wavelength autofluorescence imaging

Conditions: Retinal Disease; Retinal Degeneration; Retinal Dystrophies

Summary: fundus autofluorescence imaging has become an important diagnostic tool in ophthalmology, guiding diagnosis and assessment of progression of retinal diseases. this study investigates the performance of optimized long-wavelength autofluorescence imaging. to achieve this goal, the investigators will determine an optimal long wavelength excitation light and investigate the autofluorescence signal intensity in normals and patients with different retinal diseases. the diagnostic performance of the long-wavelength autofluorescence will be evaluated by assessing sensitivity and specificity for diagnosing a variety of degenerative retinal diseases and by comparing it to conventional autofluorescence.

fundus autofluorescence (af) imaging of the retina with confocal scanning laser ophthalmoscopy has been established as a non-invasive imaging modality for the diagnosis of retinal and macular diseases. long-wavelength near-infrared autofluorescence (excitation: 787 nm, lw-af) is a new, innovative alternative to the classic autofluorescence imaging using 488 nm blue excitation light. excitation of the fluorophores at the ocular fundus using a longer wavelength has several advantages. however, with the current imaging technique the autofluorescence signal and thus image quality is considerably lower compared to conventional short-wavelength autofluorescence (sw-af). this may be the main reason for the currently limited application and scarce scientific publications on this technique. therefore, the objective of this study is to assess the performance of an optimized setup of long-wavelength autofluorescence imaging in clinical routine applications. for this purpose, additional laser sources will be integrated into a scanning laser ophthalmoscope and the performance with regards to image quality will be investigated systematically using different excitation wavelengths and filter combinations in healthy controls. in a next step, the signal intensity will be quantified using an integrated fluorescent reference. first, factors affecting measurements will be identified, followed by generation of a normative database. subjects with various retinal diseases will then be investigated and compared to the normative database. finally, the diagnostic performance of long-wavelength autofluorescence imaging to detect retinal degenerative diseases will be investigated and compared to conventional imaging techniques.

Eligibility criteria:
inclusion criteria: * age 18 years or above * defined retinal disease (patients) or no known retinal disease (healthy participants) * participants willing to read and understand the study information and provide informed consent * participants agree to have some examinations and photographs taken from their eyes exclusion criteria: * significant opacities of the ocular media * difficulties positioning still in front of the camera * any ocular/ general disease known to affect recordings and/or analysis of retinal images * pupil diameter \<5mm
prediction of germline brca 1/2 genes from healthy ovaries

Conditions: BRCA Mutation; Ovarian Cancer; Ultrasound Therapy; Complications

Summary: the project aims at enhancing performance metrics and prospectively validating a radiogenomics model based on ovarian us images for predicting germline breast cancer susceptibility gene 1 and/or 2 (brca) status in women with healthy ovaries. the project is divided in two operational phases: retrospective phase aim 1: to define and implement a proper and fine-tuned image preprocessing pipeline on the existing dataset; aim 2: to enlarge dataset size with new real images from different centers and apply data augmentation techniques, deep neural network models combined with the aforementioned handcrafted imaging features from radiomics analysis; prospective phase aim 3: to further cross-validate the predictive model on us images acquired prospectively in an observational multicenter study.


Eligibility criteria:
inclusion criteria: availability of gbrca1/2 test results transvaginal pelvic us performed providing at least one picture of one healthy ovary us images stored in .dicom format. exclusion criteria: personal diagnosis of oc ovarian abnormal findings (eg. ovarian endometriomas, dermoid cyst, ovarian cystoadenofibroma, ovarian borderline tumour...) with the exception of functional cysts at pelvic us gbrca1/2 testing results nor provided by an iso 1589 accredited laboratory refusal to provide written informed consent
cone beam computed tomography for evaluating corticotomy-assisted maxillary expansion

Conditions: Posterior Cross Bite

Summary: maxillary expansion was performed for adult female patients suffering from maxillary constriction with bilateral posterior cross-bite using fixed quad-helix appliance, for about 8 months. the appliance was delivered and activated at the day of corticotomy and bone graft. the activation was made half-molar unit each side. the patient was scheduled each month to activate the appliance or reactivate if needed. corticotomy was performed at area of maxillary 1st premolar, 2nd premolar and first molar. cone beam computed tomography was performed, before appliance activation and corticotomy, at the end of expansion (8 months) and after finishing orthodontic treatment (average 2.5 years from start of treatment).

maxillary expansion was performed for adult female patients suffering from maxillary constriction with bilateral posterior cross-bite \& dental arch discrepancy average 12 mm using fixed quad-helix appliance, for about 8 months. the appliance was delivered and activated at the day of corticotomy and bone graft (demineralized freeze-dried bone allograft). the activation was made half-molar unit each side. the patient was scheduled each month to activate the appliance or reactivate if needed. corticotomy was performed at area of maxillary 1st premolar, 2nd premolar and first molar. cone beam computed tomography was performed at three stages. t1 (baseline) before appliance activation and corticotomy. t2 at the end of expansion. (about 8 months of expansion). t3 at the finishing stage of orthodontic treatment (average 2.5 years from start of treatment).

Eligibility criteria:
inclusion criteria: * adult female patients (18-22 years) suffering from maxillary constriction with bilateral posterior cross-bite. * dental arch discrepancy average 12 mm. exclusion criteria: * having any given systemic disease. * taking any type of medication and/or antibiotic therapy during the 3 months before the study. * didn't perform previous orthodontic treatment. * current or former smokers.
antihemostatic therapy and endoscopic biliary sphincterotomy induced bleeding

Conditions: Endoscopic Biliary Sphincterotomy; Bleeding

Summary: the aim of the study is to observe the effects of antihemostatic therapy including nonsteroidal antiinflammatory, anticoagulant and antiaggregant therapy and other patient and procedure related factors on the risk of endoscopic biliary sphincterotomy induced bleeding.


Eligibility criteria:
inclusion criteria: * hospitalization * endoscopic sphincterotomy * the patients whose warfarin treatment was stopped and inr was normalized prior to examination exclusion criteria: * the patients who had undergone endoscopic cholangiography with no sphincterotomy * outpatient procedures

Keywords: endoscopic sphincterotomy hemorrhage nonsteroidal antiinflammatory agents antiaggregants anticoagulants endoscopic biliary sphincterotomy induced bleeding